Studies a neuroblastoma tumor's genes and makeup to guide future treatment
Examines tumor and blood samples from people with neuroblastoma to learn about their cancer.
Plain-language title generated from the registry record
Registry title: Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Key facts
- Where
- New York, United StatesSee the site
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT00588068
- Record updated
- 5 October 2026
- Original description
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.Read full original descriptionShow less
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
Inclusion: Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System; OR; Clinically suspected neuroblastic tumors; PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY):; PK Draw Inclusion Criteria; Patients who receive naxitamab as part of their standard of care.
Exclusion: None.